Next 10 |
home / stock / rgnx / rgnx articles
RBC Capital Markets upgraded REGENXBIO Inc (NASDAQ:RGNX), a company focused on developing gene therapies. Recently, REGENXBIO reported ad...
REGENXBIO Inc (NASDAQ:RGNX) reported additional interim safety and efficacy data in the Phase 1/2 AFFINITY DUCHENNE trial of RGX-202 in patien...
Shares of Zscaler, Inc. (NASDAQ: ZS) shares fell sharply during Friday’s session following second-quarter results. Zscaler posted better-tha...
Last Wednesday, REGENXBIO Inc (NASDAQ:RGNX) reported additional interim safety and efficacy in the Phase 1/2 AFFINITY DUCHENNE tria...
Jim Cramer, the host of CNBC’s “Mad Money,” has suggested that investors should look beyond the Magnificent Seven tech stocks for...
Adverum Biotechnologies Inc (NASDAQ:ADVM) released preliminary safety and efficacy data from the ongoing LUNA Phase 2 trial in patients with w...
Shares of The Container Store Group, Inc. (NYSE: TCS) shares fell sharply during Wednesday’s session following weak quarterly results. Conta...
Earlier on Wednesday, REGENXBIO Inc (NASDAQ:RGNX) reported additional interim safety and efficacy in the Phase 1/2 AFFINITY DUCHENNE tria...
U.S. stocks traded higher, with the Dow Jones gaining around 150 points on Wednesday. Shares of Chipotle Mexican Grill, Inc. (NYSE: CMG) rose shar...
News, Short Squeeze, Breakout and More Instantly...
REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit PR Newswire ROCKVILLE, Md. , April 24, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in Chardan's 8th Annual Genetic ...
REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD PR Newswire A single ABBV-RGX-314 gene therapy treatment has the potential to become a new standard-of-care option among anti-VEGF treatments by sustain...
REGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days PR Newswire ROCKVILLE, Md. , March 27, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in Cantor Fitzgerald's Virtual DMD and Other Dystrop...